Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

IL-6 Kit ELISA

Ce kit ELISA Colorimetric est destiné à la mesure quantitative de Humain IL-6.
N° du produit ABIN577085
1.078,85 €
Plus frais de livraison 40,00 € et TVA
96 tests
Destination: France
Envoi sous 6 à 9 jours ouvrables

Aperçu rapide pour IL-6 Kit ELISA (ABIN577085)

Antigène

Voir toutes IL-6 (IL6) Kits ELISA
IL-6 (IL6) (Interleukin 6 (IL6))

Reactivité

  • 38
  • 21
  • 20
  • 12
  • 11
  • 10
  • 9
  • 8
  • 7
  • 6
  • 5
  • 4
  • 3
  • 3
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
Humain

Méthode de détection

Colorimetric

Type de méthode

Sandwich ELISA

Application

ELISA
  • Fonction

    This IL-6 enzyme linked immunosorbent assay (ELISA) applies a technique called a quantitative sandwich immunoassay. The microtiter plate provided in this kit has been pre-coated with a monoclonal antibody specific to IL-6. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated polyclonal antibody preparation specific for IL-6 and incubated. IL-6 if present, will bind and become immobilized by the antibody pre-coated on the wells and then be

    Analytical Method

    Quantitative

    Sensibilité

    The minimum detectable dose of IL-6 was determined by adding two standard deviations to the mean optical density value of the zero standard replicates and calculating the corresponding concentration from the standard curve. The minimum detectable dose using a standard curve generated with Calibrator Diluent I is 2.0 pg/mL and using Calibrator Diluent II is 1.75 pg/mL.

    Ingrédients

    Standards: 1 set/2 vials
  • Plaque

    Pre-coated

    Restrictions

    For Research Use only
  • Agent conservateur

    Without preservative
  • Antigène Voir toutes IL-6 (IL6) Kits ELISA

    IL-6 (IL6) (Interleukin 6 (IL6))

    Autre désignation

    Interleukin-6 (IL-6)

    Sujet

    Hepatitis B is an infection of the liver caused by the hepatitis B virus. Approximately 5-1% of adults and 9% of babies who are infected with HBV will go on to carry the virus for the rest of their lives. These people will pass the virus onto others. HBV is excreted in body fluids such as semen, saliva, blood and urine in persons with acute or chronic infection. The route of transmission can include homosexual or heterosexual activity, blood-borne exposure (needles, transfusion), mother-infant, close personal contact and even by consuming contaminated food or water. Thus, Hepatitis B has become a major public health concern. When HBV invades the body it causes liver damage through induction of auto-immunity. Liver cell injury results from cytotoxic T cell activity rather than viral cytotoxic activity. The principle screening test for detecting current (acute or chronic) HBV infection is the identification of HBsAg, an envelope lipoprotein. This is the first immunological marker, to appear in a patient's serum and exist in high quantities in the blood. Patients who are HBsAg positive develop chronic persistent hepatitis (CPH) and chronic active hepatitis (CAH). Patients with CPH usually remain in good health but those with CAH have progressive liver damage with the outcome being portal fibrosis, cirrhosis, or hepatocellular carcinoma. Screening for HBsAg is recommended for all donors, pregnant women and those individuals who at high risk. Presence of this marker is conclusive proof of HBV infection. YBL offers an immunoassay that can measure HBsAg through antigen-antibody interactions

    Pathways

    Signalisation TLR, Hormone Transport, Negative Regulation of Hormone Secretion, Myometrial Relaxation and Contraction, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Regulation of Carbohydrate Metabolic Process, Autophagy, Cell RedoxHomeostasis, Cancer Immune Checkpoints, Inflammasome
Vous êtes ici:
Chat with us!